- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02577926
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)
Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow fibrosis, and disease-related symptoms including pruritus, night sweats, fever, weight loss, cachexia, and diarrhea. In addition, due to elevated numbers of leucocytes, erythrocytes and/or platelets, the disease course can be complicated by thromboembolic disease, hemorrhage, and leukemic transformation as well as myelofibrosis.
Patients with polycythemia vera (PV) typically harbor an increased number of blood cells from all three hematopoietic cell lineages due to clonal amplification of hematopoetic stem cells, while patients with essential thrombocythemia (ET) typically show a predominant expansion of the megakaryocytic lineage. Most patients with PV below the age of 60 years are currently being treated with acetylsalicylic acid +/- phlebotomy only, and patients with low-risk ET have an almost normal life expectancy and often do not require specific treatment. However, PV- as well as ET-patients with a higher risk for complications require cytoreductive treatment. In addition, constitutional symptoms can be unbearable to patients even in the absence of bona fide high risk factors, and these patients may similarly benefit from antineoplastic therapy.
Study Overview
Status
Intervention / Treatment
Detailed Description
Polycythemia vera (PV) and essential thrombocythemia (ET) are classical Philadelphia-negative myeloproliferative neoplasms (MPN) that are characterized by an excess of cells in the peripheral blood, clonal bone marrow hyperplasia, and extramedullary hematopoiesis. The symptoms of these patients may range from asymptomatic disease to symptomatic disease that may significantly affect their activities of daily living, such as severe generalized pruritus, night sweats and fevers, erythromelalgia, bone and muscle pain, weight loss, and fatigue. Moreover, the patients may develop thromboembolic and hemorrhagic complications, transition to myelofibrosis (MF), and transformation to acute leukemia. In principle, the only potentially curative therapy for MPNs is allogenic stem cell transplantation (allo-SCT). However, due to significant transplant-associated morbidity and mortality, this therapeutic option is only applied in exceptional cases of ET or PV. The majority of patients do not qualify for allo-SCT since the risks of this treatment clearly outweigh the potential benefits. Moreover, even with a non-transplantation approach, patients with ET and PV have a life expectancy comparable to or close to healthy age-matched control persons. For patients with standard risk PV, phlebotomy and acetylsalicylic acid are standard of care (target hematocrit below 45 %), while patients with standard risk ET should receive either no specific treatment or acetylsalicylic acid (provided that no microvascular symptoms or secondary acquired von Willebrand syndrome are present).
However, in patients who are at high risk to develop thromboembolic or hemorrhagic complications (high-risk patients), cytoreductive treatment is generally indicated to prevent these potentially life-threatening complications. In PV and ET, high risk patients are characterized by advanced age (> 60 years) and / or a history of thromboembolic or hemorrhagic events {1,2,3}. In ET, a platelet count > 1500 x 109/l is associated with an increased risk of bleeding, and thus should result in a platelet lowering treatment {2}. In PV, in addition to the risk-score based therapy, cytoreduction is also required in patients with progressive or marked myeloproliferation (leukocytosis, thrombocytosis, symptomatic splenomegaly, increase of frequency of phlebotomy requirement), or devastating constitutional symptoms {1,2,4}. In Germany, best available therapy (BAT) includes approved drugs such as hydroxyurea (HU; approved for both PV and ET) and anagrelide (approved for second-line treatment of ET) and non-approved options such as alpha-interferon, pipobroman, busulfan (in elderly patients), and radioactive phosphorus (32P). In rare cases, patients may also benefit from splenic irradiation or splenectomy.
Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms. Ruxolitinib is currently studied in phase 2 and phase 3 clinical trials for HU-resistant or HU-intolerant PV and ET. The aim of the present study is to assess the feasibility, efficacy, and safety of ruxolitinib treatment vs. BAT in patients with high-risk PV or -ET.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Charite Universitätsmedizin Berlin; Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie
-
Freiburg, Germany, 79106
- Universitätsklinikum Freiburg - Klinik für Innere Medizin I
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg Eppendorf Klinik und Poliklinik für Onkologie, Hämatologie und KMT mit Sektion Pneumologie
-
Jena, Germany, 07705
- Universitätsklinik Jena - Klinik für Innere Medizin II
-
Lübeck, Germany
- UNIVERSITÄTSKLINIKUM Schleswig-Holstein - Klinik für Hämatologie und Onkologie, Campus Lübeck
-
-
Baden-Württemberg
-
Mannheim, Baden-Württemberg, Germany, 68167
- Universitätsmedizin Mannheim III. Medizinische Klinik Hämatologie und Internistische Onkologie
-
Ulm, Baden-Württemberg, Germany, 89081
- Universitätsklinikum Ulm Klinik für Innere Medizin III
-
Winnenden, Baden-Württemberg, Germany, 71364
- Rems-Murr Klinikum Winnenden
-
-
Bayern
-
Aschaffenburg, Bayern, Germany, 63739
- Studienzentrum Aschaffenburg
-
Müchen, Bayern, Germany, 81675
- III. Medizinischen Klinik des Klinikums rechts der Isar der TU München
-
Nürnberg, Bayern, Germany, 90419
- Klinikum Nürnberg Nord Medizinische Klinik 5
-
-
Hessen
-
Mainz, Hessen, Germany, 55131
- Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik
-
-
NRW
-
Aachen, NRW, Germany, 52074
- Uniklinik RWTH Aachen
-
-
Nordrhein-Westfalen
-
Bonn, Nordrhein-Westfalen, Germany, 53105
- Universitätsklinikum Bonn Medizinische Klinik und Poliklinik III
-
Duisburg, Nordrhein-Westfalen, Germany, 47228
- Johanniter-Krankenhaus Rheinhausen GmbH Hämatologie / Internistische Onkologie / Tagesklinik
-
Düsseldorf, Nordrhein-Westfalen, Germany, 40225
- Universitätsklinikum Düsseldorf Klinik für Hämatologie, Onkologie und Klinische Immunologie
-
Essen, Nordrhein-Westfalen, Germany, 45122
- Universitätsklinikum Essen Klinik für Hämatologie
-
Minden, Nordrhein-Westfalen, Germany, 32429
- Mühlenkreiskliniken Johannes Wesling Klinikum Minden Klinik für Hämatologie, Onkologie und Palliativmedizin
-
-
North Rhine Westphalia
-
Düsseldorf, North Rhine Westphalia, Germany, 40479
- Marienhospital
-
-
Sachesen-Anhalt
-
Magdeburg, Sachesen-Anhalt, Germany, 39120
- Universitätsklinikum Magdeburg
-
-
Sachsen
-
Chemnitz, Sachsen, Germany, 09113
- Klinikum Chemnitz gGmbH Klinik für Innere Medizin III
-
Dresden, Sachsen, Germany, 01307
- Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I
-
-
Sachsen-Anhalt
-
Halle (Saale), Sachsen-Anhalt, Germany, 06120
- Universitätsklinikum Halle (Saale)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must provide written informed consent prior to studyspecific procedures or assessments which are not routinely performed for diagnosis or monitoring of PV or ET, and the subjects must be willing to comply with treatment and to follow up assessments and procedures
- Patient must be 18 years of age or older
- Patient´s ECOG performance status must be 0-2
Patient must fulfill WHO 2008 diagnostic criteria for either polycythemia vera (PV) or essential thrombocythemia (ET). Moreover, PV- and ET-patients have to be classified as high risk according to defined criteria.
For patients with high risk PV OR PV with indication for cytoreductive therapy due to progressive myeloproliferation, AT LEAST ONE of the following must be fulfilled (according to DGHO onkopedia) (Barbui, et al., 2011). (Passamonti, 2009):
- Age > 60 years
- Previous documented thrombosis or thromboembolism
- Platelet count > 1500 x 109/L
- Poor tolerance of phlebotomy or frequent phlebotomy requirement
- Symptomatic or progressive splenomegaly
- Severe disease-related symptoms (according to the investigators definition)
- Progressive leukocytosis with leukocyte count > 20 x 109/L
For patients with high risk ET, AT LEAST ONE of the following must be fulfilled (according to DGHO guidelines):
- Age > 60 years
- Platelet count> 1500 x 109/L
- Previous thrombosis or thromboembolism
- Previous severe hemorrhage related to ET (defined as decrease of Hgb of at least 2 g/dl)
Patients must fulfill the following criteria regarding prior therapy:
PV patients:
Never treated with cytoreductive drugs except hydroyurea, anagrelide, or interferon for up to 6 weeks maximum (phlebotomy and/or aspirin are allowed)
ET patients:
Naïve and pretreated patients may be entered in this trial.
- Patient must have adequate liver function as indicated by a total bilirubin, AST, and ALT ≤ 2 of the institutional upper limit of normal (ULN) value, unless directly attributable to the patient's MPN
- Patient must have a creatinine clearance >40ml/min calculated according to the modified formula of Cockcroft and Gault, eGFR, or directly measured after 24h-urine collection
- Patients must be able to swallow and retain oral medication
Exclusion Criteria:
- Patients who meet criteria for post PV-MF or post ET-MF (IWG-MRT)
- Patients who have received previous ruxolitinib treatment
- Patients who have a history of anaphylaxis following exposure to the BAT drug of choice
- Patients who have an inadequate bone marrow reserve as demonstrated by ANC ≤ 1 x 109/l OR platelet count <50 x 109/l
- Patients who have known hepatitis B or C or HIV infection
- Patients who suffer from other severe, concurrent diseases, including tuberculosis, serious cardiac functional dysfunction (class III or IV as defined by the New York Heart Association Classification), uncontrolled diabetes, uncontrolled hypertension, severe pulmonary disease (i.e. COPD with hypoxemia), or major organ malfunction that could interfere with the patient's ability to participate in the study
- Patients who have history of active substance or alcohol abuse within the last year
- Female patients who are pregnant or nursing
- Patients who have participated in another interventional trial and/or used investigational agents or concurrent anticancer treatment for concomitant disease within the last 4 weeks of registration
- Any circumstance at the time of study entry that would preclude completion of the study or the required follow-up prohibits inclusion into this study
- Subjects who have had an active malignancy during the previous 3 years except for treated cervical intraepithelial neoplasia, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin, each with no evidence for recurrence in the past 3 years
- Patients who have uncontrolled bacterial, viral, or fungal infection
- Patients who have any medical condition requiring prolonged use of oral corticosteroids with a dose of more than 20 mg per day (> 1 month)
- Patients who have severe cerebral dysfunction and/or legal incapacity
- Patients who have had active splanchnic vein thrombosis within the last 3 months (includes Budd-Chiari, portal vein, splenic and mesenteric thrombosis)
- Patients who have thyroid dysfunction which is not adequately controlled
Fertile men or women of childbearing potential cannot be included unless they are:
- surgically sterile or > 2 years after the onset of menopause and/or
- willing to use a highly effective contraceptive method (Pearl Index <1) such as oral contraceptives, intrauterine device, sexual abstinence, or barrier method of contraception (i.e. condoms) in conjunction with spermicidal jelly during study treatment
Patients who are taking any of the following prohibited medication:
- clarithromycin, telithromycin, troleandomycin (antibiotics)
- ritonavir, indinavir, saquinavir, nelfinavir, amprenavir, lopinavir (HIV protease inhibitors)
- itraconazole, ketoconazole, voriconazole, fluconazole (antifungals)
- Patients with a diagnosis of galactose or lactose intolerance or a glucose-galactose- malabsortion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ruxolitinib
Ruxolitinib will be administered orally at a dose of 10 mg twice daily (both PV and ET) for two consecutive years.
|
Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis.
The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
Other Names:
|
Active Comparator: Best available therapy (BAT)
BAT may include all currently used treatment options.
BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
BAT will be administrated for two consecutive years.
|
BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The rate of complete clinicohematologic response rate (CHR) as defined by Barosi et al 2009
Time Frame: at month 6
|
at month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: at month 6 and 12
|
at month 6 and 12
|
|
The complete response rate (CR) at month 6 as defined by Barosi et al Blood 2013 (revised ELN response criteria)
Time Frame: month 6
|
month 6
|
|
The rate of complete responses (CHR) at month 12 as defined by Barosi et al Blood 2009
Time Frame: month 12
|
month 12
|
|
The efficacy as assessed by the absence of phlebotomy (Hct <45%)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
The efficacy as assessed by the reduction in spleen size (palpable spleen that is reduced by > 50% from baseline measured by palpation and ultrasound) OR platelet count < 600 x 10^9/l (ET)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Proportion of subjects achieving both durable absence of phlebotomy eligibility AND durable spleen volume reduction measured by palpation and ultrasound (PV) OR durable platelet count <600 x 10^9/l (ET) (durable defined as >3 months) {Barosi et al 2013)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
The rate of overall clinicohematologic remissions (CR + PR) according to both guidelines (Barosi et al 2009 and 2013)
Time Frame: through study completion, an average of 2 years
|
through study completion, an average of 2 years
|
|
Safety of both regimen
Time Frame: through study completion, an average of 2 years
|
Adverse events will be assessed according to CTCAE 4.0 throughout the study until 30 days after EoT for patients in both regimens
|
through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steffen Koschmieder, Prof. Dr., RWTH University Hospital MK4
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-181
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycythemia Vera (PV)
-
PharmaEssentia Japan K.K.Recruiting
-
PharmaEssentia Japan K.K.CompletedPolycythemia Vera (PV)Japan
-
PharmaEssentia Japan K.K.RecruitingPolycythemia Vera (PV)Japan
-
Novartis PharmaceuticalsCompletedPolycythemia Vera (PV)United States
-
Novartis PharmaceuticalsCompletedAsian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MFPrimary Myelofibrosis (MF) | Post-Polycythemia Vera (PV) MF | Post-Essential Thrombocythemia (ET) MFTaiwan, Japan, Korea, Republic of, China
-
Kartos Therapeutics, Inc.RecruitingPrimary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
-
GlaxoSmithKlineActive, not recruitingNeoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
-
Sierra Oncology LLC - a GSK companyCompletedPrimary Myelofibrosis (PMF) | Post-polycythemia Vera (Post-PV) Myelofibrosis | Postessential Thrombocythemia (Post-ET) MyelofibrosisUnited States, Canada
-
Sierra Oncology, Inc.CompletedPrimary Myelofibrosis (PMF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Post-polycythemia Vera (Post-PV)United States, Canada, France, Italy, Germany, Spain, Israel, United Kingdom
-
John MascarenhasRecruitingPrimary Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis | ET-MF | Post-polycythemia Vera Related Myelofibrosis | PV-MFUnited States
Clinical Trials on Ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
Incyte CorporationActive, not recruiting
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
University of JenaCompleted
-
University of Michigan Rogel Cancer CenterCompletedHemophagocytic Syndrome (HPS)United States
-
Margherita MaffioliUnknown
-
University of PittsburghWithdrawnHead and Neck Squamous Cell Carcinoma